NASDAQ$FDMT
4D Molecular Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided operational highlights.
4DMT reported positive interim data for 4D-150 in wet AMD and is on track with the 4FRONT Phase 3 program. The company's cash, cash equivalents, and marketable securities were $551 million as of September 30, 2024, expected to fund planned operations at least into H1 2027.
- Presented positive interim data for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial.
- 4D-150 4FRONT Phase 3 program in wet AMD continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025.
- Company product portfolio strategy and cash utilization updates, together with SPECTRA clinical trial program and interim data updates in diabetic macular edema (DME), expected in early January 2025.
- Cash, cash equivalents and marketable securities were $551 million as of September 30, 2024, expected to fund planned operations at least into H1 2027.
Headline financials
Revenue & EPS history
4DMT · Revenue · Quarterly
$3K
Revenue by segment
4DMT · $20.2M total across 1 segment · Q3 2023
- Collaboration & license rev.$20.2M+3940.8%100.0%
Forward guidance
4DMT anticipates several milestones in the near future.
Tailwinds
- 52-week interim data from Phase 2b cohort of PRISM clinical trial expected in February 2025.
- 4FRONT-1 Phase 3 clinical trial initiation expected in Q1 2025.
- SPECTRA clinical trial program and interim data updates expected in early January 2025.
- Phase 1 enrollment for 4D-175 for Geographic Atrophy expected to begin in Q1 2025.
- Interim data and program update from AEROW clinical trial is expected in mid-2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+1.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+20.0%
Q3 2022
Best reaction
-10.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -0.7% | -17.3% | |
| Q4 2025 | +7.3% | +7.2% | +22.5% | |
| Q3 2025 | +6.7% | +6.1% | +7.4% | |
| Q1 2025 | +9.9% | +4.7% | +27.0% | |
| Q4 2024 | -8.6% | -8.6% | -28.7% | |
| Q3 2024 | +1.9% | +5.7% | -17.4% | |
| Q2 2024 | +0.6% | +1.6% | +2.4% | |
| Q1 2024 | -2.4% | -2.2% | -13.7% | |
| Q4 2023 | +5.3% | -3.0% | +14.2% | |
| Q3 2023 | +1.8% | +2.2% | +37.7% | |
| Q2 2023 | -1.6% | -1.1% | -7.4% | |
| Q1 2023 | -2.5% | +2.8% | +26.8% | |
| Q4 2022 | -0.7% | -5.4% | -12.5% | |
| Q3 2022 | +20.0% | +66.3% | +188.5% | |
| Q2 2022 | -10.4% | -12.5% | -14.9% | |
| Q1 2022 | -3.1% | -12.9% | -31.5% | |
| Q4 2021 | +8.1% | +1.6% | -22.5% | |
| Q3 2021 | -0.7% | -3.8% | -12.1% | |
| Q2 2021 | -4.0% | +5.2% | +19.4% | |
| Q1 2021 | -3.9% | -3.4% | +2.6% | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro